Steven Schoenfeld

1.4k total citations · 1 hit paper
13 papers, 478 citations indexed

About

Steven Schoenfeld is a scholar working on Genetics, Radiology, Nuclear Medicine and Imaging and Cancer Research. According to data from OpenAlex, Steven Schoenfeld has authored 13 papers receiving a total of 478 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Genetics, 6 papers in Radiology, Nuclear Medicine and Imaging and 4 papers in Cancer Research. Recurrent topics in Steven Schoenfeld's work include Glioma Diagnosis and Treatment (8 papers), Radiomics and Machine Learning in Medical Imaging (5 papers) and Cancer, Hypoxia, and Metabolism (4 papers). Steven Schoenfeld is often cited by papers focused on Glioma Diagnosis and Treatment (8 papers), Radiomics and Machine Learning in Medical Imaging (5 papers) and Cancer, Hypoxia, and Metabolism (4 papers). Steven Schoenfeld collaborates with scholars based in United States, Netherlands and Germany. Steven Schoenfeld's co-authors include Robert G. Thompson, Orville Kolterman, Jerry P. Palmer, Shuchi S. Pandya, Lori Steelman, Paul D. Miller, Rebecca D. Jackson, Angelo A. Licata, Charles H. Chesnut and Timothy F. Cloughesy and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Diabetes Care.

In The Last Decade

Steven Schoenfeld

13 papers receiving 461 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial

2023 111 citations Ingo K. Mellinghoff, Min Lu et al. Nature Medicine profile →

Peers

Steven Schoenfeld

GENET

EDM

SURGE

ONCOL

Johanne Desjardins Canada

Rosie Head United Kingdom

H Gatica Chile

Daniela Cordella Italy

Elena Nefyodova Belgium

Yasuo Kuroki Japan

Gabriel Obiols Spain

María Jesús Lloret Spain

Holger Franz Germany

M J Delisle France

Johanne Desjardins Canada

Steven Schoenfeld

33 ×0.2

GENET

35 ×0.3

EDM

188 ×1.5

75 ×0.6

SURGE

107 ×0.9

ONCOL

Citations per year, relative to Steven Schoenfeld Steven Schoenfeld (= 1×) peers Johanne Desjardins

Countries citing papers authored by Steven Schoenfeld

Since Specialization

Citations

This map shows the geographic impact of Steven Schoenfeld's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Schoenfeld with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Schoenfeld more than expected).

Fields of papers citing papers by Steven Schoenfeld

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Schoenfeld. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Schoenfeld. The network helps show where Steven Schoenfeld may publish in the future.

Co-authorship network of co-authors of Steven Schoenfeld

This figure shows the co-authorship network connecting the top 25 collaborators of Steven Schoenfeld. A scholar is included among the top collaborators of Steven Schoenfeld based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven Schoenfeld. Steven Schoenfeld is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Mellinghoff, Ingo K., Min Lu, Patrick Y. Wen, et al.. (2023). Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. Nature Medicine. 29(3). 615–622. 111 indexed citations breakdown →

Mellinghoff, Ingo K., Martin J. van den Bent, Deborah T. Blumenthal, et al.. (2023). INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.. Journal of Clinical Oncology. 41(17_suppl). LBA1–LBA1. 8 indexed citations

Schoenfeld, Steven, et al.. (2022). Thematic Indexes: Expanding Dimensions of Indexing. 13(1). 69–78. 1 indexed citations

Mellinghoff, Ingo K., Martin J. van den Bent, Jennifer Clarke, et al.. (2020). RTID-05. INDIGO: A GLOBAL, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF VORASIDENIB (AG-881) VS PLACEBO IN PATIENTS WITH RESIDUAL/RECURRENT GRADE II GLIOMA WITH AN ISOCITRATE DEHYDROGENASE 1/2 (IDH1/2) MUTATION. Neuro-Oncology. 22(Supplement_2). ii194–ii194. 2 indexed citations

Mellinghoff, Ingo K., Martin J. van den Bent, Jennifer Clarke, et al.. (2020). INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation.. Journal of Clinical Oncology. 38(15_suppl). TPS2574–TPS2574. 11 indexed citations

Mellinghoff, Ingo K., Timothy F. Cloughesy, Patrick Y. Wen, et al.. (2019). A phase I, open label, perioperative study of AG-120 and AG-881 in recurrent IDH1 mutant, low-grade glioma: Results from cohort 1.. Journal of Clinical Oncology. 37(15_suppl). 2003–2003. 23 indexed citations

Mellinghoff, Ingo K., Marta Peñas-Prado, Katherine B. Peters, et al.. (2018). ACTR-31. PHASE 1 STUDY OF AG-881, AN INHIBITOR OF MUTANT IDH1 AND IDH2: RESULTS FROM THE RECURRENT/PROGRESSIVE GLIOMA POPULATION. Neuro-Oncology. 20(suppl_6). vi18–vi18. 9 indexed citations

Mellinghoff, Ingo K., Marta Peñas-Prado, Katherine B. Peters, et al.. (2018). Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma.. Journal of Clinical Oncology. 36(15_suppl). 2002–2002. 24 indexed citations

Thompson, Robert G., et al.. (1998). Pramlintide, a Synthetic Analog of Human Amylin, Improves the Metabolic Profile of Patients With Type 2 Diabetes Using Insulin. Diabetes Care. 21(6). 987–993. 71 indexed citations

10.

Miller, Paul D., Nelson B. Watts, Angelo A. Licata, et al.. (1997). Cyclical Etidronate in the Treatment of Postmenopausal Osteoporosis. The American Journal of Medicine. 103(6). 468–476. 107 indexed citations

11.

McCulloch, David K., Leslie J. Klaff, Steven E. Kahn, et al.. (1990). Nonprogression of Subclinical β-Cell Dysfunction Among First-Degree Relatives of IDDM Patients: 5-Yr Follow-Up of the Seattle Family Study. Diabetes. 39(5). 549–556. 64 indexed citations

12.

Miller, Douglas C., et al.. (1989). Non-Hodgkin’s Lymphoma of the Central Nervous System after Treatment of Hodgkin’s Disease. American Journal of Clinical Pathology. 91(4). 481–485. 15 indexed citations

13.

Wilkin, Terence J., Steven Schoenfeld, José-Luis Dı́az, et al.. (1989). Systematic Variation and Differences in Insulin-Autoantibody Measurements. Diabetes. 38(2). 172–181. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact